Meggitt Training Systems to Extol World-Leading Training Products at Levels of Fidelity 2015

Meggitt Training Systems, an industry-leading, turnkey provider of design, development, equipment and installation of military live-fire training ranges, will exhibit at the 2015 Levels of Fidelity annual conference in Walenstadt, Switzerland. From Oct. 19-21, 2015, Meggitt representatives will discuss the products and technologies that are bringing more and more international service outfits to choose Meggitt as a strategic partner.

The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin) and RAPLIXA™ (sealant powder)

The Medicines Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued positive opinions recommending marketing authorization for three of its pipeline development candidates – KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin), and RAPLIXA™ (sealant powder). These positive opinion recommendations represent category firsts across three therapeutic areas:

New Study Finds Positive Impact of Remittances More Widespread than Previously Thought

The University of Colorado Boulder Leeds School of Business, which includes the well-regarded Business Research Division, and The Western Union Company (NYSE:WU), a leader in global payment services, today announced the release of a first-of-its-kind study that sheds new light on the positive impact of cross-border money transfer broadly and of Western Union services in particular.

MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma

MSD, known as Merck in the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed pembrolizumab, the company’s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540).1 At six months, the PFS rates for pembrolizumab were 34 percent at the 2 mg/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months.1

Ecolab’s Apex Warewashing System Helps Restaurant and Foodservice Operators Throughout Europe Improve Results, Save Water and Energy

Ecolab Inc., the global leader in water, hygiene and energy technologies and services, has launched Apex, a warewashing system that will provide the cleaning results restaurant and foodservice operators throughout Europe expect, while reducing water and energy use.

NetJets Europe to Take Delivery of Signature Series™ Challenger 350 Aircraft

The fractional ownership leader, NetJets Europe, has today announced that it will be taking delivery of the Signature Series™ Challenger 350 aircraft from Bombardier Business Aircraft. The all new Challenger 350 will join the European fleet as an industry leading super-midsize aircraft in mid-2015, following the delivery this summer to NetJets US. The additional aircraft on order are scheduled to arrive over the next few years.

Otsuka and The Union Announce Global TB Research & Innovation Award

In recognition of World TB Day 2014, Otsuka SA (Otsuka), in a global partnership with the International Union Against Tuberculosis and Lung Disease (The Union), today issued a call for nominations for its Young Innovator in TB Research Award, aimed at recognizing young scientists who have demonstrated a commitment to advancing innovative thinking in tuberculosis (TB) research.